Trials / Completed
CompletedNCT00451880
Study of XL281 in Adults With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL281 Administered Orally to Subjects With Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- Sponsor
- Exelixis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safest dose of the multiple Raf kinase inhibitor (including c-Raf, B-Raf, and the activated mutant B-RafV600E) XL281, how often it should be taken, and how well subjects with cancer tolerate XL281. This study will also determine how the body reacts to XL281 when it is taken with and without food, and with and without Pepcid (famotidine), a drug that inhibits stomach acid production.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XL281 | Gelatin capsules supplied as 5-, 25-, and 100-mg strengths |
| DRUG | famotidine | single dose, supplied as 20-mg or 40-mg tablets |
Timeline
- Start date
- 2007-02-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2007-03-26
- Last updated
- 2011-10-13
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00451880. Inclusion in this directory is not an endorsement.